The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of children and adolescent patients with Bipolar I mania.
Treatment, Placebo Control, Safety/Efficacy Study
Eligibility & Criteria
Inclusion Criteria:- Patient is able to provide written assent and the parents or legal guardian of the patient is able to provide written informed consent before beginning and study related procedures – Patient has a documented clinical diagnosis of Bipolar I mania – Patientâs parent or legal guardian will be able to accompany the patient at each scheduled study visit Exclusion Criteria:- Patients (female) must not be pregnant or lactating – Patients with a known intolerance or lack of response to previous treatment with quetiapine – Patients who have previously participated in this study
AstraZeneca Information Center (8 AM â 7 PM EST) 1-800-236-9933
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.